CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up roughly 3.8% of ARK Investment’s disclosed equity portfolio at ...

TriLink BioTechnologies senior scientist Dr Cody Palumbo discusses the blockers to manufacturing mRNA-based gene editing ...

The CAP committee recommended that pathologists use mass spectrometry to determine the subtype for amyloidosis patients being considered for treatment.

This article examines some of the cell-based approaches that researchers are using to study acquired drug resistance and the ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...

Korro Bio saw its stock reach all-time lows on disappointing data for its lead pipeline candidate, while Intellia Therapeutics saw analyst downgrades on safety concerns despite releasing positive data ...

This article and associated images are based on a poster originally authored by Daniela Flehberger, Sofia Buianova, Emma Langguth, Johanna Irnstorfer, Stefanie Fellinger, Henrik Schmidt, Adam Krejci, ...

On Saturday, CRISPR Therapeutics AG (NASDAQ:CRSP) shared Phase 1 data from its ongoing clinical trial evaluating CTX310, an investigational, in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3.

-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ...

Revvity's Dharmacon All-in-one lentiviral platform has expanded to include whole-genome library options for CRISPR knockout (CRISPRko), CRISPR interference (CRISPRi), and CRISPR activation (CRISPRa).

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...